AKTX earnings analysis
What we found in AKTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q extract contains no reported revenue, margin, EPS, cash-flow, balance-sheet, or segment figures, preventing a period-over-period operating trend analysis. The principal disclosed development is that remediation efforts were implemented, but disclosure controls remained ineffective as of June 30, 2026 pending testing. Risk remains elevated because approximately $30.3 million of IPR&D is subject to potential impairment and the company has relied on $8.3 million and $5.5 million capital raises for funding.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Control remediation implemented
- Management states that remediation efforts for the previously identified control deficiencies have already been implemented as of June 30, 2026, subject to testing over a sufficient period.
- $30.3M development-asset base
- The company reported approximately $30.3 million of IPR&D as of June 30, 2026, principally related to AKTX-101 and its ADC Platform, supporting the value of its development portfolio.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material control weaknesses persist
- Disclosure controls and procedures were still not effective at a reasonable assurance level as of June 30, 2026, due to previously identified material weaknesses involving QuickBooks IT/general controls and purchase-to-pay controls.
- IPR&D impairment exposure
- Approximately $30.3 million of IPR&D remains exposed to future impairment. The filing identifies adverse clinical, regulatory, competitive, pricing and financing-market developments as potential triggers for significant impairment charges.
- Ongoing financing dependence
- The company raised $8.3 million in Q2 2026 after a prior $5.5 million capital offering, highlighting continued dependence on external financing; repeated equity financing may create dilution and does not establish recurring operating cash flow.
What they said about what is next.
No quantitative revenue or EPS outlook is provided in the filing extract; no explicit guidance was disclosed.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 19, 2026
- Akari Therapeutics' Q1 2026 results reflect a significant increase in operational losses, primarily due to non-cash impairment charges. With $2.8 million in cash and accumulated deficits approaching $279 million, the…
- 10-K · March 30, 2026
- Akari Therapeutics positions itself as an ADC-focused oncology company centered on a novel spliceosome-targeting payload (PH1) and is advancing lead ADC AKTX-101 toward IND-enabling studies with a goal of a…
- 10-K · March 29, 2024
- Akari is a clinical-stage biotech focused on nomacopan (a dual C5 and LTB4 inhibitor) with multiple orphan/fast-track designations and ongoing pediatric Phase 3 work in HSCT‑TMA. The 10‑K discloses a near‑term strategic…
- 10-Q · August 12, 2015
- Celsus reported a narrower operating loss in Q2 2015 of $1,456k versus $2,330k in Q2 2014, driven largely by a sharp reduction in R&D spend after suspension of its MRX‑6 program. Cash fell to $2,718k at June 30, 2015…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AKTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever